EMEA-002963-PIP01-21
Key facts
| Active substance |
Propan-2-yl (2S)-2-{[(S)-({(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)-9H-purin-9-yl]-4-fluoro-3- hydroxy-4-methyloxolan-2-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate; sulfuric acid (2:1) (AT-527 / RO7496998)
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0463/2021
|
| PIP number |
EMEA-002963-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Atea Pharmaceuticals, Inc.
Email: Dept-regulatory@ateapharma.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|